# Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents

> **NCT02402933** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 26 (actual)

## Conditions studied

- Hypoglycemia
- Diabetes Mellitus

## Interventions

- **DRUG:** Nasal Glucagon

## Key facts

- **NCT ID:** NCT02402933
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2015-03
- **Primary completion:** 2015-08
- **Final completion:** 2015-08
- **Target enrollment:** 26 (ACTUAL)
- **Last updated:** 2019-09-23


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02402933

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02402933, "Clinical Usability of Nasal Glucagon in Treatment of Hypoglycemia in Children and Adolescents". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02402933. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*